<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583373</url>
  </required_header>
  <id_info>
    <org_study_id>CAL02-001</org_study_id>
    <nct_id>NCT02583373</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae</brief_title>
  <official_title>Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Combioxin SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Combioxin SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety, tolerability, clinical and&#xD;
      microbiological efficacy and pharmacodynamics of patients who have severe pneumonia caused by&#xD;
      Streptococcus pneumoniae after the intravenous administration of CAL02 in addition of&#xD;
      standard of care antibiotic treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Streptococcus pneumoniae is the most frequently identified pathogen of community-acquired&#xD;
      bacterial pneumonia and its severe forms are associated with high morbidity and mortality,&#xD;
      despite pneumococcal vaccines and medical treatment (antibiotic therapy, alone or in&#xD;
      combination). Bacterial toxins, such as the pore-forming toxin (PFT) pneumolysin (from&#xD;
      Streptococcus pneumoniae), are involved in the development of invasive disease and play a key&#xD;
      role in severe and fatal complications. CAL02 offers a novel therapeutic approach by&#xD;
      neutralising bacterial toxins, such as pneumolysin, which recognise specific microdomains on&#xD;
      host cell membranes, called lipid rafts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 21, 2016</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">February 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and characteristics of adverse events after two iv. administrations of CAL02.</measure>
    <time_frame>29 days</time_frame>
    <description>To determine the safety profile of CAL02</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy: cure.</measure>
    <time_frame>29 days.</time_frame>
    <description>Complete resolution of signs and symptoms of pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effects.</measure>
    <time_frame>29 days.</time_frame>
    <description>Measuring biomarkers (CRP/PCT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological efficacy.</measure>
    <time_frame>29 days.</time_frame>
    <description>Eradication: baseline isolate not present in repeat culture from original infection site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival.</measure>
    <time_frame>29 days</time_frame>
    <description>Assessment of 28 days all cause mortality.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Pneumonia</condition>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>CAL02 Low-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CAL02 High-dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liposomal formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAL02 Low-dose</intervention_name>
    <description>Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion</description>
    <arm_group_label>CAL02 Low-dose</arm_group_label>
    <other_name>CAL02 LD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAL02 High-dose</intervention_name>
    <description>Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion</description>
    <arm_group_label>CAL02 High-dose</arm_group_label>
    <other_name>CAL02 HD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered administered 2 times (24 hours apart) as i.v. infusion</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo CAL02</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male or female patients ≥ 18 years and ≤ 80 years of age&#xD;
&#xD;
          -  Body weight 40-140 kg&#xD;
&#xD;
          -  Severe pneumonia caused by Streptococcus pneumoniae managed in an ICU&#xD;
&#xD;
          -  CURB-65 score ≥ 3 in patients aged &gt; 65 and CURB-65 ≥ 2 in patients aged &lt; 65&#xD;
&#xD;
          -  Streptococcus pneumoniae identification with the urine antigen test or any other&#xD;
             proven documented identification method&#xD;
&#xD;
          -  Written informed consent provided by the patient, the relatives or the designated&#xD;
             trusted person and/or according to local guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hospital-acquired-, health care-acquired- or ventilator-&#xD;
             associated-pneumonia&#xD;
&#xD;
          -  More than (i) 12 hours since diagnosis of severe CAPP and (ii) 24 hours or 60 hours&#xD;
             since antibiotic treatment IV or per os, respectively, unless documented not to be&#xD;
             active against S. pneumoniae, will have elapsed at the time of IMP administration&#xD;
&#xD;
          -  APACHE II score &gt; 30 points&#xD;
&#xD;
          -  SOFA score &gt; 12 points&#xD;
&#xD;
          -  Inability to maintain a mean arterial pressure ≥ 50 mm Hg&#xD;
&#xD;
          -  Known hypersensitivity to liposomal formulations&#xD;
&#xD;
          -  Patients with severe neutropenia or lymphoma or current or anticipated chemotherapy&#xD;
&#xD;
          -  End-stage neuromuscular disorders&#xD;
&#xD;
          -  Patients who have long-term tracheostomy&#xD;
&#xD;
          -  Current or recent participation in an investigational study&#xD;
&#xD;
          -  Presence of other pneumococcal site infection&#xD;
&#xD;
          -  Patients with known acquired immune deficiency syndrome (AIDS) with CD4 count &lt; 200&#xD;
             cells/mL&#xD;
&#xD;
          -  Patients with known post-obstructive pneumonia (active primary lung cancer or another&#xD;
             malignancy metastatic to the lungs)&#xD;
&#xD;
          -  Patients with cystic fibrosis, Pneumocystis jiroveci pneumonia, or active tuberculosis&#xD;
&#xD;
          -  Patients receiving immunosuppressant therapy&#xD;
&#xD;
          -  Patients with a known liver function deficiency&#xD;
&#xD;
          -  Splenectomised patients&#xD;
&#xD;
          -  Patients who have experienced an allergic reaction to eggs&#xD;
&#xD;
          -  Moribund clinical condition&#xD;
&#xD;
          -  Nursing and pregnant women&#xD;
&#xD;
          -  Women of child bearing potential not using an effective contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BRUNO FRANCOIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Limoges CHU Dupuytren 2 Avenue Martin Luther King 87042 Limoges Cedex, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Luc University Hospital</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brussels</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique St Pierre</name>
      <address>
        <city>Ottignies</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHD Les Oudairies</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional d'ORLEANS</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30805-3/fulltext</url>
    <description>CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial</description>
  </link>
  <link>
    <url>https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30070-2/fulltext</url>
    <description>Lancet ID editorial: One step closer to precision medicine for infectious diseases</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Streptococcus pneumoniae</keyword>
  <keyword>Pneumolysin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

